Subscribe To
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Olpx investor notice: robbins geller rudman & dowd llp announces that olaplex holdings, inc. investors with substantial losses have opportunity to lead class action lawsuit
SAN DIEGO, Dec. 10, 2022 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Olaplex Holdi...
December 10, 2022, 9:12 pm
Fate therapeutics highlights ipsc-derived, off-the-shelf car nk cell programs for multiple myeloma at 2022 ash annual meeting
Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose Escalation Cohorts as Monotherapy and in C...
December 10, 2022, 7:46 pm
Sutro biopharma announces presentation of stro-002 data from the compassionate use program in pediatric patients with relapsed/refractory cbf/glis aml at ash 2022
– A total of 17 pediatric patients were treated with STRO-002 on a compassionate use basis; eight patients achieved complete remission, of which sev...
December 10, 2022, 3:30 pm
Sgly class action deadline alert: johnson fistel encourages shareholders to submit their singularity losses
SAN DIEGO, Dec. 10, 2022 (GLOBE NEWSWIRE) — Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on b...
December 10, 2022, 3:22 pm
Fate therapeutics announces clinical safety and activity data of first-ever ipsc-derived car t-cell therapy at 2022 ash annual meeting
FT819 Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Engineered Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC...
December 10, 2022, 3:00 pm
Vertex and crispr therapeutics to present at the american society of hematology (ash) annual meeting and exposition
BOSTON and ZUG, Switzerland--( BUSINESS WIRE )--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announ...
December 10, 2022, 8:00 am
Ada lovelace’s skills with language, music and needlepoint contributed to her pioneering work in computing
By Corinna Schlombs, Rochester Institute of Technology Ada Lovelace, known as the first computer programmer, was born on Dec. 10, 1815, more than a ce...
December 9, 2022, 7:31 pm
Silvergate class action deadline alert: johnson fistel encourages shareholders to submit their si losses
SAN DIEGO, Dec. 09, 2022 (GLOBE NEWSWIRE) — Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on b...
December 9, 2022, 2:10 pm
Why elon musk thinks lucid (lcid) stock is about to die
There's an interesting dichotomy building in today's market. Electric vehicle (EV) leader Tesla (NASDAQ: TSLA ) is up more than 4% at the time of thi...
December 9, 2022, 1:11 pm
Erasca announces exclusive worldwide license for pan-raf inhibitor naporafenib
Concurrent $100 million equity offering Naporafenib has a potential first-in-class and best-in-class profile in multiple RAS/MAPK pathway-driven tumor...
December 9, 2022, 12:34 pm
Erasca announces pricing of underwritten offering of common stock
SAN DIEGO, Dec. 09, 2022 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discoveri...
December 9, 2022, 12:32 pm
Li auto inc. (li) q3 2022 earnings call transcript
Li Auto Inc. (NASDAQ:LI ) Q3 2022 Results Conference Call December 9, 2022 7:00 AM ET Company Participants Janet Zhang - Investor Relations Director K...
December 9, 2022, 12:00 pm
Major drilling group international inc. (mjdlf) q2 2023 earnings call transcript
Major Drilling Group International Inc. (OTCPK:MJDLF) Q2 2023 Earnings Conference Call December 9, 2022 9:00 AM ET Company Participants Denis Larocque...
December 9, 2022, 11:45 am